The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients
The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients
批准号:
10284166
负责人:
Christopher James Gibson
金额:
$21.99万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-01 至 2026-08-31
关键词:
Acute Myelocytic LeukemiaAdvisory CommitteesAffectAllogenicAreaBiologic CharacteristicBiological AssayBiological ProcessBiologyBiometryBone MarrowCardiovascular DiseasesCaringCellsCharacteristicsClinicalClonal EvolutionClonal ExpansionCollaborationsCommunitiesCyclophosphamideDana-Farber Cancer InstituteDataData ScienceDevelopment PlansDiseaseDisease remissionDonor SelectionDonor personEngraftmentEnvironmentGenesGenomicsGoalsHematologic NeoplasmsHematopoiesisHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHistologicImmuneImmune EvasionImmune systemImmunologic SurveillanceImmunologicsImmunologyImpairmentIndividualInflammatoryInterventionInvestigationLeukocytesMediatingMentorshipModalityMutateMutationMyeloid CellsOutcomeOutputPathogenicityPathway interactionsPatientsPatternPhysiciansPopulationRecurrent diseaseRelapseResearchResearch PersonnelResidual stateRiskSamplingScientistShapesSignal TransductionSomatic MutationStem cell transplantT-Cell DevelopmentT-LymphocyteT-Lymphocyte SubsetsTechniquesTestingTimeToxic effectTrainingTransplant RecipientsTransplantationWorkadverse outcomeage relatedbasecancer cellcareercareer developmentcell typecurative treatmentscytokinecytopeniadisorder riskexhaustionexperimental studygraft failuregraft functiongraft vs leukemia effecthematopoietic cell transplantationimprovedimproved outcomeinsightleukemia relapsemutantnovelnovel strategiesnovel therapeutic interventionpost-transplantpressurerelapse risksingle cell technologysuccess
中文摘要
项目摘要/摘要
造血细胞移植是治疗恶性血液病的重要手段。
(HM)。它的成功取决于捐赠者的造血细胞建立长期造血和
免疫介导性消除残留的恶性细胞。克隆性造血(CH)是与年龄相关的
可检测到的体细胞突变改变其生物功能和炎症输出的状态
造血细胞,在非移植人群中与不良后果一致相关。通过
研究了1727对HCT供受者,我发现捐赠者中的CH很常见,而且失活突变
在基因中,DNMT3A是最常见的变化。我的初步数据显示供体DNMT3A-CH是
通过降低HM复发风险,改善全球受者结局,但也
增加了一部分受者移植失败的风险。根据这些数据和已知的函数
在造血细胞中的DNMT3A,我假设供者DNMT3A-CH I在HCT受者中观察到的效果
是由于DNMT3A突变的长期造血干细胞植入和随后的功能改变
在成熟的DNMT3A突变的白细胞亚群中,特别是T细胞。为了检验这一假设,我提出了以下建议
目的有二:(1)研究DNMT3A-CH对HCT后正常和受损造血功能的影响。这就做
使用基因组、免疫表型和单细胞技术来定义特征,包括细胞
移植到受体体内的供体DNMT3A突变的隔室。然后我将专注于阐明生物学
供体DNMT3A-CH受者发生移植物衰竭的风险。(2)界定DNMT3A-CH在供体-
移植后植入的T细胞。我将使用基因组、免疫表型和单细胞技术
检测供体DNMT3A突变对术后受者T细胞组成和功能的影响
特别关注DNMT3A突变如何调节T细胞耗竭的发展。
然后我将专门评估捐赠者T细胞中的DNMT3A突变如何影响免疫逃避的途径
用于急性髓系白血病复发病例。从这些研究中获得的信息将提供
对移植后造血和免疫监测生物学的新见解可能会有深远的影响
供者选择的含义和增强移植物抗白血病效应的策略。与
在拟议的实验中,我概述了一个五年职业发展计划,目标是成为一名
翻译移植研究中的独立调查者。我已经组建了一个全球顾问委员会
公认的造血、移植免疫学和生物统计学专家,提供实验投入
以及在这些领域的具体培训。达纳-法伯癌症研究所,该研究所拥有一项杰出的研究
社区,并且有成功指导独立内科科学家的长期记录,是一个理想的选择
为完成这些实验和实现我的短期和长期职业目标提供环境。
英文摘要
PROJECT SUMMARY/ABSTRACT
Hematopoietic cell transplant (HCT) is an important treatment modality for patients with hematologic malignancy
(HM). Its success depends on the ability of donor hematopoietic cells to establish long-term hematopoiesis and
immunologically mediated elimination of residual malignant cells. Clonal hematopoiesis (CH) is an age-related
condition in which detectable somatic mutations alter the biologic function and inflammatory output of
hematopoietic cells, and in non-transplant populations is uniformly associated with adverse outcomes. By
studying 1727 HCT donor-recipient pairs, I found that CH in donors is common and that inactivating mutations
in the gene DNMT3A are the most frequent alterations. My preliminary data shows that donor DNMT3A-CH is
associated with improved global recipient outcomes, mediated by a reduced risk of HM relapse, but also
increases the risk of graft failure in a subset of recipients. Based on these data and the known function of
DNMT3A in hematopoietic cells, I hypothesize that the effects of donor DNMT3A-CH I observe in HCT recipients
are due to engraftment of DNMT3A-mutated long-term hematopoietic stem cells and subsequent altered function
in mature DNMT3A-mutant leukocyte subsets, particularly T cells. To test this hypothesis, I propose the following
two aims: (1) Determine the effect of DNMT3A-CH on normal and impaired hematopoiesis following HCT. I will
use genomic, immunophenotypic, and single-cell technologies to define the characteristics, including cellular
compartment, of donor DNMT3A mutations that engraft in recipients. I will then focus on elucidating the biology
of graft failure developing in recipients of donor DNMT3A-CH. (2) Define the effect of DNMT3A-CH in donor-
engrafted T-cells after transplantation. I will use genomic, immunophenotypic, and single-cell techniques to
determine the effect of donor DNMT3A mutations on T-cell composition and function in recipients after
transplantation, focusing specifically on how DNMT3A mutations modulate the development of T-cell exhaustion.
I will then specifically assess how donor DNMT3A mutations in T cells affect the pathways of immune evasion
utilized by relapsing cases of acute myeloid leukemia. The information gained from these studies will provide
new insights into the biology of post-transplant hematopoiesis and immune surveillance that could have profound
implications for donor selection and strategies to augment the graft-versus-leukemia effect. In concert with the
proposed experiments, I have outlined a five-year career development plan aimed at the goal of becoming an
independent investigator in translational transplant research. I have assembled an advisory committee of globally
recognized experts in hematopoiesis, transplant immunology, and biostatistics, to provide experimental input
and specific training in these fields. Dana-Farber Cancer Institute, which harbors an outstanding research
community and has a long track record for successful mentorship of independent physician scientists, is an ideal
environment for completion of these experiments and realization of my short and long-term career goals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients
-
批准号:10471977
-
项目类别:
-
资助金额:$21.99万
-
财政年份:2021
-
负责人:Christopher James Gibson
-
依托单位:
海外基金